Phase 2 N=48 Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=301 Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens
Myopia and Hyperopia and Presbyopia
Primary: Proportion of Subjects Agreeing With the Statement "Clear Vision: Near, Far, and In-between — 241 Participants
Phase 4 N=9 Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF
Heart Failure · Heart Failure, Diastolic · Heart Failure With Preserved Ejection Fraction
Primary: Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative…
N/A N=47 Supporting Self-Management of Healthy Behaviors in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Feasibility: Adoption — 44; 42; 18; 22 Participants
Phase 3 N=220 Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Congenital Heart Defects
Primary: Time To Extubation — 46.9; 48.0 hours — p=<.05
N/A N=127 Continuous Intraosseous Vascular Access Over 48 Hours
Intraosseous Vascular Access
Primary: Serious Complications From Intraosseous (IO) Access — 0; 0; 0; 0 Participants
Phase 4 N=65 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
Bipolar Depression
Primary: Response to Treatment — 21; 9; 6; 11 Participants — p=.02
Phase 1 N=30 A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants
Healthy
Primary: Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C — 10920; 10720; 11200…
Phase 3 N=187 Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Rett Syndrome
Primary: Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12 — -4.9; -1.7 score on a scale — p=0.0175
Phase 3 N=228 Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Oropharynx Cancer
Primary: Grade 3+ Adverse Events Rate — .032; .115 events per participant
Phase 2 N=207 Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
Healthy
Primary: Comparison of Minimum Percent Inhibition Platelet Reactivity Unit (PRU) Assessed by VerifyNow™ PRUTest™ From Baseline to Within 4 Hours After Study Drug Start. — -5.99…
N/A N=35 Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence Products
Urinary Incontinence
Primary: Number of Manual Checks Per Day at Baseline Week and 3 Weeks — 3.5; 4.3 Checks per day — p=0.0006
N/A N=80 Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
Peripheral Neuropathy · Stage 0 Breast Cancer · Stage I Breast Cancer
Primary: Tibial Nerve Cross-sectional Area — 13.0; 14.0 mm^2
Phase 2 N=10 Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Primary: Overall Response Rate at Week 16 (4 Weeks After the End of Treatment) — 88.9; 80.0 percentage of participants
Phase 3 N=288 A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
Herpes Zoster
Primary: Percentage of Participants Showing a Vaccine Response for Anti-glycoprotein E (gE) — 85.7; 7.8 Percentage of participants